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Gil-Perotin et al. ask if the relapsing patients we identified as having 
silent progression are identical to the previously described category 
bout onset progressive MS (BOPMS). The authors refer to an earlier 
paper by Paz Soldán et al. that uses the BOPMS term to refer to what is
otherwise known as secondary progressive MS (SPMS). SPMS is 
recognized as progressive worsening independent from relapses after 
a relapsing disease onset. SPMS is typically recognized many years 
after disease onset and only after substantial disability has 
accumulated corresponding to expanded disability status scale (EDSS) 
scores of 4.0 to 6.0. In our recent publication, we found evidence of 
insidious worsening independent from relapsing activity (clinical or 
radiographic) in patients who were considered by their providers to still
have relapsing remitting multiple sclerosis (RRMS). These silent 
progressors were not recognized as having SPMS (or “BOMPS” as Gil-
Perotin et al. seem to prefer). The phenomenon of silent progression is 
more akin to the concept of “progression independent of relapse 
activity” (PIRA), as we referenced in our manuscript.1
The authors also raise an interesting question with respect to the long-
term fate of persons living with MS: are there two groups of RRMS 
patients, one whose fate is to develop progression and a second who 
will not? Perhaps this is the case; however, it is more likely that larger 
numbers of patients with RRMS will be identified as having progression 
as the observation time lengthens and more sensitive indices of 
neurologic change are employed. For example, we and others have 
shown that combining EDSS with other measures such as cognitive 
function, walking speed, and upper limb function will increase the 
proportion of RRMS patients found to have relapse-independent 
progression. We agree with the authors that a common 
pathophysiology may well underlie silent progression and SPMS. The 
key point of our manuscript is that it is important to recognize silent 
progression during RRMS thereby prompting a therapeutic switch to 
treatments known to slow disability accumulation in patients with 
progressive MS.2,3 Whether early escalation to high potency therapies, 
or their use at disease onset, prevents SPMS remains to be 
determined.
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